SRD5A2
ENSG00000277893
Target class
Enzyme
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- SRD5A2
- Gene name
- Steroid 5 alpha-reductase 2
- Gene symbol
- SRD5A2
- Protein name
- 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (EC 1.3.1.22) (5 alpha-SR2) (SR type 2) (Steroid 5-alpha-reductase 2) (S5AR 2) (Type II 5-alpha reductase)
- Gene biotype
- Protein coding
- Gene family
- Steroid 5-alpha reductase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 25.75
- Tissue specificity (Gini)
- 0.929
- Tissue specificity (tau)
- 0.985
- KEGG gene identifiers
- hsa:6716
- Reactome pathways
- R-HSA-193048
- Protein interaction confidence
- 0.878321
- Protein interaction partners
- 28
- End position
- 31580941
- Start position
- 31522480
- Chromosome
- 2
- Strand
- Reverse
- Microsome membrane
- Multi-pass membrane protein. Endoplasmic reticulum membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.984627
- Expression inequality (Gini)
- 0.929132
Expression in transcripts per million
- Prostate
- 25.75
- Liver
- 11.22
- Testis
- 3.74
- Vagina
- 2.32
- Cervix - Endocervix
- 0.67
Expression in transcripts per million
- Prostate25.75
- Liver11.22
- Testis3.74
- Vagina2.32
- Cervix - Endocervix0.67
- Cervix - Ectocervix0.64
- Fallopian Tube0.54
- Lung0.23
- Bladder0.22
- Muscle - Skeletal0.12
- Kidney - Cortex0.11
- Brain - Cerebellar Hemisphere0.1
- Brain - Cerebellum0.09
- Breast - Mammary Tissue0.07
- Pituitary0.07
- Minor Salivary Gland0.06
- Uterus0.06
- Skin - Not Sun Exposed (Suprapubic)0.05
- Adrenal Gland0.05
- Ovary0.05
- Skin - Sun Exposed (Lower leg)0.04
- Brain - Hypothalamus0.04
- Spleen0.04
- Adipose - Subcutaneous0.04
- Stomach0.03
And 29 more, listed on the interactive page.
- GO:0006702
- GO:0007267
- GO:0008209
- GO:0008584
- GO:0061370
Cellular components
- GO:0005789
- GO:0003865
- GO:0005515
- GO:0047045
- GO:0047751
Related records
Trials (242)
- "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
- 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
- 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
- 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
- 5-Alpha Reductase and Anabolic Effects of Testosterone
- A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol
- A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
- A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers
- A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
- A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects
- A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions
- A Clinical Study of Curcuvail® in Patients With Non-alcoholic Fatty Liver Disease
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
- A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Trial Comparing Laser TURP With and Without Dutasteride.
- A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
- A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
Drugs (3)
- Abiraterone Steroid 5-alpha-reductase inhibitor
- Dutasteride Steroid 5-alpha-reductase inhibitor
- Finasteride Steroid 5-alpha-reductase 2 inhibitor